Press Release argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026 Aug 3
Press Release argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline Jul 26